Stocks›Healthcare›BMRN

BMRN

BIOMARIN PHARMACEUTICAL INC

NasdaqResearch view

$60.26−1.78%

Sep 25 close · 1D EOD · Databento

HealthcarePharmaceutical PreparationsLarge-capSEC EDGAR FY 2025-12-31

What happened

Daily closes · dots are Wire stories

1 story has a settled receipt so far (1 on the Wire). The record starts speaking at three.

What’s next

Expected around early November, going by its own filing history. The company has not announced a date yet. Its matching report came Oct 27, 2025 and Oct 29, 2024, after the close.

Last report

Aug 6, 2026+3.82%

after the close

Last 4, next close

median 2.42% either way

up 2 of 4

Every report since 2023 →

DateEventSourceNext close

Aug 31BioMarin Announces Global Settlement with Ascendis Pharma A/S; Ascendis Will Pay Royalties to BioMarin on Yuviwel Sales in U.S., EU, Brazil and South KoreaPR NewswirePR Newswire+0.87%
Aug 6Earnings release, after the close · 8-KSEC EDGARSEC EDGAR ↗+3.82%

Next close = the first close after the event against the close before it. Prior-session closes only; not a call, not advice.

Big days · last year

Daily closes · Databento EOD

15 big days: a close more than 3.25% from the one before, three times BMRN’s median day (1.08%). On 5 of 15, its largest peers moved the same way at least half as far. We show what we hold, never a cause.

Shaded: since our stories began, May 26, 2026

15Sep 2, 2026
Sep 2, 2026Nothing in our recordNo BMRN story, brief or results filing in our record that dayGroup +0.9% did not move with it
+0.9% did not move with itJNJ +1.5 · MRK +1.2 · ABBV +0.7 · LLY +0.0
+3.29%
14Aug 19, 2026
Aug 19, 2026Nothing in our recordNo BMRN story, brief or results filing in our record that dayGroup +3.6% moved the same way
+3.6% moved the same wayMRK +12.6 · LLY +4.5 · ABBV +2.7 · JNJ +0.8
+3.49%
13Aug 10, 2026
Aug 10, 2026Nothing in our recordNo BMRN story, brief or results filing in our record that dayGroup +1.4% did not move with it
+1.4% did not move with itLLY +3.9 · MRK +1.8 · JNJ +1.0 · ABBV +0.8
+7.95%
12Aug 7, 2026
Aug 7, 2026ResultsThe first close after a results filing (SEC 8-K, Item 2.02)Group +0.5% did not move with it
+0.5% did not move with itABBV +0.9 · JNJ +0.9 · LLY −0.5 · MRK +0.2
+3.82%
11Jun 4, 2026
Jun 4, 2026Nothing in our recordNo BMRN story, brief or results filing in our record that dayGroup +4.0% moved the same way
+4.0% moved the same wayMRK +4.8 · LLY +4.3 · ABBV +3.6 · JNJ +2.2
+3.31%
10Jun 1, 2026
Jun 1, 2026Nothing in our recordNo BMRN story, brief or results filing in our record that dayGroup −2.1% moved the same way
−2.1% moved the same wayMRK −3.0 · ABBV −2.2 · LLY −2.1 · JNJ −0.8
−3.94%
9May 29, 2026
May 29, 2026Nothing in our recordNo BMRN story, brief or results filing in our record that dayGroup −1.5% did not move with it
−1.5% did not move with itJNJ −2.4 · LLY −1.9 · MRK −1.0 · ABBV −0.4
+8.63%
8May 21, 2026
May 21, 2026Before our storiesGroup +1.6% did not move with it
+1.6% did not move with itMRK +2.5 · LLY +2.2 · JNJ +1.1 · ABBV +1.0
+7.77%
7May 18, 2026
May 18, 2026Before our storiesGroup +0.3% did not move with it
+0.3% did not move with itLLY −1.7 · MRK +1.1 · JNJ +1.0 · ABBV −0.5
−4.13%
6May 5, 2026
May 5, 2026ResultsThe first close after a results filing (SEC 8-K, Item 2.02)Group +0.3% did not move with it
+0.3% did not move with itLLY +2.2 · ABBV −1.0 · JNJ +0.6 · MRK +0.0
−4.00%
5Jan 13, 2026
Jan 13, 2026ResultsThe first close after a results filing (SEC 8-K, Item 2.02)Group −0.0% did not move with it
−0.0% did not move with itJNJ +1.9 · MRK −0.8 · LLY −0.3 · ABBV +0.3
−4.35%
4Dec 19, 2025
Dec 19, 2025Before our storiesGroup +0.9% did not move with it
+0.9% did not move with itABBV +1.8 · LLY +1.4 · JNJ −0.9 · MRK +0.4
+17.71%
3Nov 21, 2025
Nov 21, 2025Before our storiesGroup +2.3% moved the same way
+2.3% moved the same wayABBV +3.0 · MRK +2.9 · LLY +1.6 · JNJ +0.4
+4.21%
2Nov 11, 2025
Nov 11, 2025Before our storiesGroup +2.9% moved the same way
+2.9% moved the same wayMRK +4.8 · ABBV +3.0 · JNJ +2.9 · LLY +2.3
+4.29%
1Oct 27, 2025
Oct 27, 2025Before our storiesGroup +0.1% did not move with it
+0.1% did not move with itMRK +0.6 · LLY +0.1 · JNJ −0.1 · ABBV +0.0
−3.32%

A story on the same day is not a cause, and a group move is not proof either. Group: LLY, JNJ, ABBV, MRK, the largest companies in BMRN’s SEC industry; “the same way” means the same direction and at least half as far. Prior-session closes only; not a call, not advice.

The numbers · FY2025, filed

SEC EDGAR

Market cap$11.7B

Revenue$3.2B+12.90%

Net income$348.9M

EPS, diluted$1.80−18.60%

Operating margin12.7%

Return on equity5.7%

Debt / equity0.10

All filed figures

Snapshot

SEC EDGAR · FY 2025-12-31

SectorHealthcare

Market Cap$11.7B

Enterprise Value$11.0B

Income$348.9M

Sales$3.2B

Book/sh$31.45

Cash/sh$6.78

Dividend TTM—

Payout—

Employees—

IPO—

Quick Ratio3.50

Current Ratio5.21

Debt/Eq0.10

EPS (ttm)$1.80

EPS this Y-18.6%

EPS past 3/5Y33.9%

Sales past 3/5Y15.4%

EPS Y/Y TTM-18.6%

Sales Y/Y TTM12.9%

Shs Outstand193.57M

ROA4.6%

ROE5.7%

ROIC5.5%

Gross Margin—

Oper. Margin12.7%

Profit Margin10.8%

Every figure here is filed with the SEC. Valuation and estimate metrics (P/E, PEG, EV/EBITDA, price targets, forward EPS) are omitted until our market-data feed is licensed for display — we’d rather show fewer numbers than blank ones. Deeper lines (cash flow, balance sheet) below.

Revenue by fiscal year

$1.8B

FY21

$2.1B

FY22

$2.4B

FY23

$2.9B

FY24

$3.2B

FY25

Operating leverage — margins

GrossOperatingNet

Financials, annual · income and cash flowSEC EDGAR · open ▸

Financials — annual

SEC EDGAR · last 5 FY · tap a row to explain it

USD	FY2021	FY2022	FY2023	FY2024	FY2025
Revenue	$1.8B	$2.1B	$2.4B	$2.9B	$3.2B
Gross Profit	—	—	—	—	—
Operating Income	$-82.3M	$161.0M	$185.8M	$484.2M	$409.5M
Net Income	$-64.1M	$141.6M	$167.6M	$426.9M	$348.9M
Diluted EPS	$-0.35	$0.75	$0.87	$2.21	$1.80
Operating Cash Flow	$304.5M	$175.9M	$159.3M	$572.8M	$828.0M
Free Cash Flow	$209.0M	$54.9M	$62.6M	$487.4M	$725.0M

Same industry

In the screener →

LLY$1.11T JNJ$653.6B ABBV$467.1B MRK$367.1B ABT$175.3B PFE$163.4B VRTX$133.4B BMY$128.4B

Follow the news. Track the move.

BMRN story timeline

Company updates and connected market context, with the dated price move attached.

Stories

Direct

Sector context/Regulation

Aug 31

BioMarin Announces Global Settlement with Ascendis Pharma A/S; Ascendis Will Pay Royalties to BioMarin on Yuviwel Sales in U.S., EU, Brazil and South Korea

BioMarin reached a global settlement with Ascendis Pharma that ends all pending patent proceedings and gives BioMarin royalties on Yuviwel sales in the U.S., EU, Brazil and South Korea. The agreement removes a legal overhang for BMRN, but the specific royalty rates and expected financial contribution remain undisclosed, leaving the market without enough detail for a strong earnings read.

Since story

-7.6%

2026-08-31 → 2026-09-25

PR Newswire · 27d ago

View both sides →

Follow the news. Track the move.